���ϳԹ���

When patients describe chest pain as coming from the heart, they are often prescribed stress tests that use a specialized radiological scan for diagnosis, prognosis or treatment monitoring.

The repetitive scans expose more than just the heart to radiation and can also result in images that are less than clear. , a cardiologist at the ���ϳԹ��� of ���ϳԹ���’s , has created a way to deliver radiation straight to the heart with the aim of alleviating both of these problems. ����

“During these tests, the radiation goes everywhere; it goes into the liver, the lungs and the gut to name a few organs. Because the gut is so close to the heart, it can sometimes cause images to be difficult to interpret,” Zahid said. “By sending the radiation only to where it’s needed for imaging, you can reduce the amount of radiation by as much as 80 percent. We are hypothesizing that this will also lead to higher image quality.”

These specific stress tests are “the biggest contributor to radiation that patients receive in the course of medical treatment,” she said.��A published in 2011 in the National Center for Biotechnology Information showed that such scans performed annually in the United States could result in 7,400 additional future cancer cases. Zahid said that there are other types of stress tests, but they are less common and less favored.

Her research led to the creation of a novel non-naturally occurring 12-amino acid peptide — peptides are molecules made up of links of amino acids that are the building blocks of proteins — called the Cardiac Targeting Peptide. It intravenously transports radioisotopes needed for stress test scans and is designed to be taken up only by cardiomyocytes — cells that make up the heart muscle. The radiation therefore doesn’t spread to other organs and, unlike the course for current stress tests, the peptide then leaves the heart and is excreted through the kidneys, sparing the liver.

Zahid said this took about two years and six attempts to get right.

“The last attempt, I told myself, ‘if this doesn’t work, I’m going to give up,’” she said. “It worked, and we found a peptide that we were able to manufacture in the ���ϳԹ���’s Peptide Synthesis Facility.”

Zahid’s peptide won first place at the Pitt’s�� (CTSI) 2016 (PInCh), with the $100,000 in winnings going toward advancing Zahid’s research findings toward clinical application.

She also was recently received��the American Heart Association Investigator Award for $210,000.

Zahid and her co-inventor, Paul Robbins, a molecular medicine professor at the Scripps Research Institute in Jupiter, Florida, have been granted a U.S. patent on the peptide technology and are planning a startup company, CardioTrak, for the near future.